Features | Partner Sites | Information | LinkXpress
Sign In
SEEGENE
FOCUS DIAGNOSTICS, INC.
AB Sciex

Project Focuses on Discovery of Early Cancer in Women

By Labmedica International staff writers
Posted on 26 Feb 2013
Scientists are focusing on the early detection of breast and ovarian cancer with the goal of developing a test to identify tumor markers present in blood and link these markers to the presence of cancer.

Partners in the project called EpiFemCare, include GATC Biotech (Constance Germany), which will manage sample processing, i.e., the DNA isolation from serum and the reduced representation bisulfite sequencing from serum derived DNA. This method analyses DNA methylation in normal and tumor DNA.

In addition, 6 institutions from 5 European countries combining clinical, scientific, and industrial expertise will add a new dimension to the treatment of cancer in women. The USD 7.8 million project from the European Commission will develop and test new methods for screening, diagnosing, and personalizing treatment of breast and ovarian cancer.

“We are proud of being a partner within the development of a DNA-based blood test that promotes new ways of diagnosing and treating patients with breast or ovarian cancer. The processing of samples in our ISO 17025 certified Genome & Diagnostic Center is one of our key competences”, commented Peter Pohl, CEO of GATC Biotech AG.

The collaborative project is led by Prof. Martin Widschwendter from the Department of Women’s Cancer at the University College London (United Kingdom). Collaborators include Charles University (Prague, Czech Republic), Ludwig Maximilians University (Munich, Germany), and companies with expertise in epigenetics and next generation screening (GATC Biotech, Germany), managing, and analyzing the large volumes of data created by these experiments (Genedata; Switzerland).

Implementation of successful screening programs has dramatically reduced the number of women dying from cervical cancer. Similarly, the EpiFemCare project aims to reduce the number of women who receive a diagnosis of breast or ovarian cancer when that cancer is already advanced by 50%, also reduce the number of women who receive unnecessary long-term chemotherapy by 50%, and reduce the number of women dying from these female cancers by 20%.

Related Links:

GATC Biotech
Department of Women’s Cancer at the University College London



GREINER-BIO-ONE
PURITAN MEDICAL
ADVANCED INSTRUMENTS
BioConferenceLive

Channels

Hematology

view channel

Blood Donations Screened for Viruses Using Multiplex Assay

A global healthcare company was chosen to partner the Japanese Red Cross (JRC; Tokyo, Japan) for nucleic acid screening of the nation's blood supply. Under the terms of the 7-year agreement, the healthcare company, Grifols (Barcelona, Spain) will provide the JRC with its newest automation platform, the Procleix Panther... Read more

Pathology

view channel

Gene Profile Predicts Risk of Bladder Cancer Recurrence

A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status. Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment.... Read more

Industry News

view channel

Beckman Coulter and hc1.com Enter Strategic Partnership for Innovative Healthcare Cloud System

The diagnostics division of Beckman Coulter (Brea, CA, USA) and hc1.com (Indianapolis, IN, USA) have announced a partnership to bring an innovative healthcare cloud-technology system to clinical laboratories. The system, hc1.com's "Healthcare Relationship Cloud," helps turn large amounts of clinical data into actionable... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.